Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.E. Molitch.
Prolactinoma.
Pituitary, pp. 433-477
[2.]
L.G. Sobrinho.
Familial prolactinoma.
Clin Endocrinol, 43 (1995), pp. 511
[3.]
J.A. Schlechte.
Clinical practice. Prolactinoma.
N Engl J Med, 349 (2003), pp. 2035-2041
[4.]
J. Verhelst, R. Abs.
Hyperprolactinaemia: pathophysiology and management.
Treat Endocrinol, 2 (2003), pp. 23-32
[5.]
B. Verges, F. Boureille, P. Goudet, A. Murat, A. Beckers, G. Sassolas, et al.
Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study.
J Clin Endocrinol Metab, 87 (2002), pp. 457-465
[6.]
M. Misra, G.I. Papakostas, A. Klibanski.
Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism.
J Clin Psychiatry, 65 (2004), pp. 1607-1618
[7.]
A. Klibanski, B.M. Biller, D.I. Rosenthal, D.A. Schoenfeld, V. Saxe.
Effects of prolactin and estrogen deficiency in amenorrheic bone loss.
J Clin Endocrinol Metab, 67 (1988), pp. 124-130
[8.]
H.L. Fideleff, H.R. Boquete, A. Sequera, M. Suarez, P. Sobrado, A. Giaccio.
Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches.
J Pediatr Endocrinol Metab, 13 (2000), pp. 261-267
[9.]
A. Giustina, M. Gola, M. Doga, E.A. Rosei.
Clinical review 136: primary lymphoma of the pituitary: an emerging clinical entity.
J Clin Endocrinol Metab, 86 (2001), pp. 4567-4575
[10.]
R.A. Yazigi, C.H. Quintero, W.A. Salameh.
Prolactin disorders.
Fertil Steril, 67 (1997), pp. 215-225
[11.]
M.E. Molitch.
Medical management of prolactin-secreting pituitary adenomas.
Pituitary, 5 (2002), pp. 55-65
[12.]
M.E. Molitch.
Medication-induced hyperprolactinaemia.
Mayo Clin Proc, 80 (2005), pp. 1050-1057
[13.]
A. Giustina, A. Barkan, F.F. Casanueva, F. Cavagnini, L. Frohman, K. Ho, et al.
Criteria for cure of acromegaly: a consensus statement.
J Clin Endocrinol Metab, 85 (2000), pp. 526-529
[14.]
J. Gibney, T.P. Smith, T.J. McKenna.
The impact on clinical practice of routine screening for macroprolactin.
J Clin Endocrinol Metab, 90 (2005), pp. 3927-3932
[15.]
O.M. Hauache, A.J. Rocha, A.C. Maia, R.M. Maciel, J.G. Vieira.
Screening for macroprolactinaemia and pituitary imaging studies.
Clin Endocrinol, 57 (2002), pp. 327-331
[16.]
M.S. Petakov, S.S. Damjanovic, M.M. Nikolic-Durovic, Z.L. Dragojlovic, S. Obradovic, M.S. Gligorovic, et al.
Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect.
J Endocrinol Invest, 21 (1998), pp. 184-188
[17.]
E. St-Jean, F. Blain, R. Comtois.
High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas.
Clin Endocrinol, 44 (1996), pp. 305-309
[18.]
H.A. Sawers, O.J. Robb, D. Walmsley, F.M. Strachan, J. Shaw, J.S. Bevan.
An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonanceimaging of the pituitary in the evaluation of hyperprolactinaemia.
Clin Endocrinol, 46 (1997), pp. 321-326
[19.]
M.J. Naidich, E.J. Russell.
Current approaches to imaging of the sellar region and pituitary.
Endocrinol Metab Clin North Am, 28 (1999), pp. 45-79
[20.]
FF. Casanueva.
Enfermedades del hipotalamo y la adenohipofisis.
Internal Medicine Textbook, 15.a ed, pp. 2018-2046
[21.]
M.E. Molitch, R.L. Elton, R.E. Blackwell, B. Caldwell, R.J. Chang, R. Jaffe, et al.
Bromocriptine as primary therapy for prolactinsecreting macroadenomas: results of a prospective multicenter study.
J Clin Endocrinol Metab, 60 (1985), pp. 698-705
[22.]
J.S. Bevan, J. Webster, C.W. Burke, M.F. Scanlon.
Dopamine agonists and pituitary tumour shrinkage.
Endocr Rev, 13 (1992), pp. 220-240
[23.]
A. Colao, A. Di Sarno, F. Sarnacchiaro, D. Ferone, G. Di Renzo, B. Merola, et al.
Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
J Clin Endocrinol Metab, 82 (1997), pp. 876-883
[24.]
C.I. Ferrari, R. Abs, J.S. Bevan, G. Brabant, E. Ciccarelli, T. Motta, et al.
Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
Clin Endocrinol, 46 (1997), pp. 409-413
[25.]
J. Verhelst, R. Abs, D. Maiter, A. Van den Bruel, M. Vandeweghe, B. Velkeniers, et al.
Cabergoline in the treatment of hyperprolactinaemia: a study in 455 patients.
J Clin Endocrinol Metab, 84 (1999), pp. 2518-2522
[26.]
J. Webster, G. Piscitelli, A. Polli, C.I. Ferrari, I. Ismail, M.F. Scanlon.
A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhoea. Cabergoline Comparative Study Group.
N Engl J Med, 331 (1994), pp. 904-909
[27.]
W.J. Jeffcoate, N. Pound, N.D. Sturrock, J. Lambourne.
Long-term follow-up of patients with hyperprolactinaemia.
Clin Endocrinol, 45 (1996), pp. 299-303
[28.]
J.A. Schlechte, B.M. Sherman, F.K. Chapler, J. VanGilder.
Longterm follow-up of women with surgically treated prolactinsecreting pituitary tumours.
J Clin Endocrinol Metab, 62 (1986), pp. 1296-1301
[29.]
S. Karunakaran, R.C. Page, J.A. Wass.
The effect of the menopause on prolactin levels in patients with hyperprolactinaemia.
Clin Endocrinol, 54 (2001), pp. 295-300
[30.]
J. Schlechte, K. Dolan, B. Sherman, F. Chapler, A. Luciano.
The natural history of untreated hyperprolactinaemia: a prospective analysis.
J Clin Endocrinol Metab, 68 (1989), pp. 412-418
[31.]
V. Popovic, M. Simic, L. Ilic, D. Micic, S. Damjanovic, M. Djurovic, et al.
Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
Clin Endocrinol, 48 (1998), pp. 103-108
[32.]
A. Colao, A. Di Sarno, M.L. Landi, F. Scavuzzo, P. Cappabianca, R. Pivonello, et al.
Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
J Clin Endocrinol Metab, 85 (2000), pp. 2247-2252
[34.]
J.S. Bevan, C.B. Adams, C.W. Burke, K.E. Morton, A.J. Molyneux, R.A. Moore, et al.
Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy.
Clin Endocrinol, 26 (1987), pp. 541-556
[35.]
M. Losa, P. Mortini, R. Barzaghi, L. Gioia, M. Giovanelli.
Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome.
J Clin Endocrinol Metab, 87 (2002), pp. 3180-3186
[36.]
P. Nomikos, M. Buchfelder, R. Fahlbusch.
Current management of prolactinomas.
J Neuro-Oncol, 54 (2001), pp. 139-150
[37.]
J.A. Thomson, D.L. Davies, E.H. McLaren, G.M. Teasdale.
Ten year follow up of microprolactinoma treated by transsphenoidal surgery.
BMJ, 309 (1994), pp. 1409-1410
[38.]
A.T. Nelson Jr., H.S. Tucker Jr., D.P. Becker.
Residual anterior pituitary function following transsphenoidal resection of pituitary macroadenomas.
J Neurosurg, 61 (1984), pp. 577-580
[39.]
P. Konopka, J.P. Raymond, R.E. Merceron, J. Seneze.
Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas.
Am J Obstet Gynecol, 146 (1983), pp. 935-938
[40.]
P. Krupp, C. Monka.
Bromocriptine in pregnancy: safety aspects.
Klin Wochenschr, 65 (1987), pp. 823-827
[41.]
E. Ciccarelli, S. Grottoli, P. Razzore, D. Gaia, A. Bertagna, S. Cirillo, et al.
Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumourous hyperprolactinaemia and outcome of drug-induced pregnancy.
J Endocrinol Invest, 20 (1997), pp. 547-551
[42.]
J. Jones, T. Bashir, J. Olney, T. Wheatley.
Cabergoline treatment for a large macroprolactinoma throughout pregnancy.
J Obstet Gynecol, 17 (1997), pp. 375-376
[43.]
C. Liu, J.B. Tyrrell.
Successful treatment of a large macroprolactinoma with cabergoline during pregnancy.
Pituitary, 4 (2001), pp. 179-185
[44.]
M.E. Molitch.
Pregnancy and the hyperprolactinemic woman.
N Engl J Med, 312 (1985), pp. 1364-1370
[45.]
M.E. Molitch.
Management of prolactinomas during pregnancy.
J Reprod Med, 44 (1999), pp. 1121-1126
[46.]
E. Ricci, F. Parazzini, T. Motta, C.I. Ferrari, A. Colao, A. Clavenna, et al.
Pregnancy outcome after cabergoline treatment in early weeks of gestation.
Reprod Toxicol, 16 (2002), pp. 791-793
[47.]
E. Robert, L. Musatti, G. Piscitelli, C.I. Ferrari.
Pregnancy outcome after treatment with the ergot derivative, cabergoline.
Reprod Toxicol, 10 (1996), pp. 333-337
[48.]
D. Beltrame, M. Longo, G. Mazue.
Reproductive toxicity of cabergoline in mice, rats, and rabbits.
Reprod Toxicol, 10 (1996), pp. 471-483
[49.]
M.J. Kupersmith, C. Rosenberg, D. Kleinberg.
Visual loss in pregnant women with pituitary adenomas.
Ann Intern Med, 121 (1994), pp. 473-477
[50.]
D.G. Johnston, K. Hall, P. Kendall-Taylor, D. Patrick, M. Watson, D.B. Cook.
Effect of dopamine agonist withdrawal after longterm therapy in prolactinomas: studies with high-definition computerised tomography.
Lancet, 2 (1984), pp. 187-192
[51.]
V.Q. Passos, J.J. Souza, N.R. Musolino, M.D. Bronstein.
Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.
J Clin Endocrinol Metab, 87 (2002), pp. 3578-3582
[52.]
A. Colao, A. Di Sarno, P. Cappabianca, C. Di Somma, R. Pivonello, G. Lombardi.
Withdrawal of long-term cabergoline therapy for tumoural and nontumoural hyperprolactinaemia.
N Engl J Med, 349 (2003), pp. 2023-2033
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición